Pharmaceutical Technology

NOVEMBER 17, 2022

Despite affecting nearly one in ten women in the UK alone, endometriosis still lacks proper research, funding, and disease awareness among both the medical community and the public. As a result, women wait eight years on average for a diagnosis after initial symptom onset, a figure that has not changed in a decade.

Hormones 257

Hormones Compliance Research 257

World of DTC Marketing

MAY 7, 2021

Though Facebook does not offer advertisers categories that explicitly identify people’s health conditions, The Markup identified dozens of ads for prescription pharmaceuticals targeted at people with “interests” in topics like “bourbon,” “oxygen,” and “Diabetes mellitus awareness.”.

Marketing 283

Marketing Drugs 283

pharmaphorum

NOVEMBER 14, 2022

Sanofi and Regeneron’s Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The post Dupixent nears EU approval for rare skin disease prurigo nodularis appeared first on. Sales of Dupixent rocketed 45% to around $2.4

Sales 117

Sales Immune Response Drugs Medicine 117

XTalks

MAY 31, 2022

This cream by Dermavant is the first steroid-free topical medication in its class. Psoriasis is a well-recognized skin disease. This immune-mediated inflammatory disease has been researched thoroughly. The disease usually develops around 15 to 25 years of age and can recur at any point of time in the affected individual’s life.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

Pharma Marketing Network

DECEMBER 6, 2021

NEW YORK, December 6 th , 2021 (PRNEWSWIRE) – Tap Native, the leading health-focused content discovery platform, today unveiled a list of the top 20 most popular health topics viewed by consumer audiences in 2021. million unique URLs across the top 100 largest health websites in its network to determine which topics were viewed most.

Engineer 52

Engineer Vaccination Vaccine Production 52

pharmaphorum

JULY 19, 2022

The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. million people in the US.

Sales 98

Sales FDA Approval Regulation Drugs 98

Rethinking Clinical Trials

DECEMBER 20, 2022

Topic Discussions. UH3 Project: Improving Chronic Disease Management with Pieces (ICD-Pieces ) - Miguel A. Branch Chief, Clinical Research in Complementary and Integrative Health. Division of Extramural Research. National Center for Complementary and Integrative Health (NCCIH). National Institutes of Health DHHS. Vazquez, MD.

Trials 130

Trials Clinical Trials Clinical Trials Research 130

The Pharma Data

NOVEMBER 4, 2020

Adults Had Chronic Pain in 2019. adults reported chronic pain in the last three months, according to a November data brief published by the U.S. Centers for Disease Control and Prevention National Center for Health Statistics. percent of adults had chronic pain in 2019, and 7.4 Professional. Percent of U.S. Zelaya, Ph.D.,

Research 52

Research 52

pharmaphorum

OCTOBER 22, 2021

Sanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin disease. The post Dupixent scores a first in rare skin disease prurigo nodularis appeared first on.

Trials 105

Trials Sales Antibody Drugs 105

Pharmaceutical Technology

NOVEMBER 29, 2022

Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome. On November 14, the Canadian developer PharmaTher announced positive data from a Phase I/II study where ketamine was used to treat levodopa-induced dyskinesia in Parkinson’s disease. In November 2021, the Michael J.

Research 275

Research Trials Drugs Generic Drugs 275

The Pharma Data

MAY 31, 2022

if approved Acceptance marks another important step in advancing Dupixent for a broad range of diseases with underlying type 2 inflammation. Both trials met the primary and key secondary endpoints, showing Dupixent significantly improved disease signs and symptoms compared to placebo, including reduction in itch and skin lesions.

Genetics 52

Genetics Antibody Medicine Trials 52

pharmaphorum

SEPTEMBER 29, 2022

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease following a priority review. Here is a patient (*written consent obtained) I saw just 2 weeks ago with severe disease. — Brian S.

Drugs 68

Drugs Immune Response Allergies Sales 68

pharmaphorum

MAY 31, 2022

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN). The post FDA grants speedy review to Dupixent rare skin disease appeared first on.

Sales 115

Sales Drugs Antibody Regulation 115

Intouch Solutions

MARCH 19, 2024

They are more likely than men to suffer chronic conditions and use prescription drugs across all age groups. They are disproportionately affected by cardiovascular disease, autoimmune diseases, migraines and osteoporosis. Women represent more of the health care system than men.

Marketing 59

Marketing Branding Doctors Doctor 59

The Pharma Data

FEBRUARY 13, 2022

FDA a ccepts Dupixent ® (dupilumab) for Priority Review in c hildren a ged 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis. Atopic dermatitis is a chronic type 2 inflammatory skin disease, and 85 to 90% of patients develop symptoms (onset of disease) before 5 years of age, which can often continue through adulthood.

Medicine 40

Medicine Genetics Antibody Allergies 40

ACRP blog

JANUARY 18, 2024

Romie) founder of the brainSHIFT Institute and the newly named Chief Wellness Officer for Great Wolf Resorts, will share her expertise on stress management and workplace wellness topics with attendees of the ACRP 2024 conference in Anaheim, Calif.

Research 59

Research Clinical Research Engineer Medicine 59

pharmaphorum

DECEMBER 18, 2020

Integrating personal experiences and patient-reported data, Health Union recently hosted a one-day virtual event entitled The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experience , featuring real-time conversations between people living with chronic conditions and industry experts. How can pharma keep up?

58

58

The Pharma Data

DECEMBER 17, 2020

17, 2020 — Tiny particles of air pollution were already known to raise people’s risk of developing heart and lung disease, but a new study suggests they might also raise the risk of developing chronic kidney disease. of participants had chronic kidney disease. times higher odds of having the disease.

Research 52

Research Development 52

The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024.

Medicine 52

Medicine Sales Clinical Development Development 52

pharmaphorum

SEPTEMBER 28, 2020

The DHCoE has a network of experts that are available for FDA staff to consult with on topics such as artificial intelligence, wearables, digital therapeutics , real-world evidence, and cybersecurity. Its remit will be to support and encourage developers, including newcomers to healthcare, to translate new technology into usable products.

Radiology 144

Radiology Production Development Regulation 144

Olympian Clinical Research

FEBRUARY 22, 2024

Hidradenitis suppurativa (HS) is a chronic skin condition characterized by painful lumps under the skin, primarily in areas where skin rubs together, like the armpits, groin, and under the breasts. Managing HS can be challenging due to its chronic nature and the significant impact it has on patients’ quality of life.

Clinical Research 52

Clinical Research Clinical Trials Clinical Trials Research 52

The Pharma Data

OCTOBER 20, 2020

Kidney Disease, Injury Linked to Higher Mortality With COVID-19. The researchers found that 58 percent of patients presented with COVID-19 and renal impairment (45 percent developed acute kidney injury [AKI] during their ICU stay and 13 percent had preexisting chronic kidney disease [CKD]). Professional. TUESDAY, Oct.

Development 52

Development Research 52

Roots Analysis

FEBRUARY 22, 2024

The rising prevalence of chronic diseases has resulted in rise in the associated co-morbidities, including wounds, mental health disorders, vascular disorders, sensory impairments, and others. The below figure illustrates the various types of chronic and acute wounds. due to the presence of associated wounds.

Production 40

Production Dermatology Marketing Development 40

The Pharma Data

MARCH 23, 2022

This outcome represents a continuation of our effort to develop new therapeutic approaches to treat immuno-inflammatory diseases and address the need for oral therapies for UC patients with inadequate response, loss of response, or intolerance to conventional or advanced therapies.”. About Etrasimod. About Ulcerative Colitis.

Trials 52

Trials Dermatology Development Medicine 52

The Pharma Data

MARCH 25, 2021

The study evaluated the safety and efficacy of two doses of abrocitinib, 100mg and 200mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. AD is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.

Medicine 52

Medicine 52

pharmaphorum

JULY 19, 2021

The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light therapy. Download the PDF here.

Development 58

Development Dermatology 58

The Pharma Data

MAY 15, 2023

These first published Phase 3 results in this disease show Dupixent significantly reduced itch (the primary endpoint) and skin lesions compared to placebo. The disease is often painful, with burning, stinging and tingling of the skin and can negatively affect mental health, activities of daily living and social interactions.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

The Pharma Data

MARCH 4, 2021

IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis and eosinophilic esophagitis. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Genetics 52

Genetics Medicine Antibody Trials 52

Druggist

APRIL 3, 2021

Diltiazem cream (diltiazem hydrochloride cream) is a medicine prescribed in the UK to manage chronic anal fissure. The legal classification of topical diltiazem . Topical diltiazem: legal classification. Chronic: symptoms present for longer than six weeks. How often to apply diltiazem topical cream?

Pharmacy 81

Pharmacy Doctors Doctor Containment 81

Drug Discovery World

DECEMBER 13, 2022

Rocatinlimab inhibits OX40 – an immune molecule involved in activating inflammatory cells that play a key role in the development of atopic dermatitis and other inflammatory diseases. . All active dose cohorts also continued improving after week 16, and most patients maintained the response for at least 20 weeks off-treatment. .

Dermatology 52

Dermatology Clinical Trials Clinical Trials Antibody 52

The Pharma Data

APRIL 7, 2021

A total of 33 abstracts, including one podium presentation during the Clinical Trials Plenary Session and three oral presentations, will be shared from a broad range of studies across the spectrum of migraine, advanced Parkinson’s disease and spasticity. vice president, neuroscience development, AbbVie. S15: Headache 2.

Botox 52

Botox Clinical Trials Clinical Trials Trials 52

pharmaphorum

NOVEMBER 1, 2022

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

pharmaphorum

MAY 18, 2021

Ruxolitinib is a topical Janus kinase (JAK) inhibitor that could provide an alternative to the steroids commonly used to treat these skin conditions, although these drugs have some undesirable side-effects. Over-activity of the JAK signalling pathway has been shown to drive the inflammation that causes vitiligo and drives its progression.

Trials 52

Trials Dermatology FDA Approval Medicine 52

The Pharma Data

MARCH 13, 2022

Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases. In particular, we’re hopeful that we can accelerate clinical development of etrasimod successfully to have a positive impact on those living with these debilitating diseases.”.

Dermatology 52

Dermatology Cardiology Development Medicine 52

pharmaphorum

JANUARY 19, 2023

It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Pharma and healthcare together can tackle chronic diseases.

Life Science 95

Life Science Vaccination Vaccine Genome 95

The Pharma Data

OCTOBER 30, 2020

from the New York University Grossman School of Medicine in New York City, and colleagues reviewed data on dyslipidemia and atherosclerotic cardiovascular disease risk in patients with endocrine disorders. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Newman, M.D.,

Medicine 52

Medicine 52

Sciensano

FEBRUARY 14, 2022

Type of press: Press release Associated health topics: Physical exercise Chronic disease Lifestyle risk factors Summary measures of population health Contact person(s): Brecht Devleesschauwer , Aline Scohy Partners: National Institute for Health and Disability Insurance (INAMI-RIZIV) Published on: Monday, February 14, 2022 Language.

52

52